What is the administration route for Apretude, a form of cabotegravir?

Apretude, which contains cabotegravir, is designed to be administered via the intramuscular route. This method allows for the medication to be delivered directly into the muscle tissue, from which it can enter the bloodstream and provide long-lasting effectiveness. The intramuscular administration supports extended release, which is key in providing consistent and sustained drug levels, particularly for the prevention of HIV infection.

Using the intramuscular route for Apretude means that patients benefit from less frequent dosing compared to oral forms, making adherence easier and improving overall effectiveness in preventative treatment. This method capitalizes on the pharmacokinetics of cabotegravir, allowing for gradual absorption and prolonged action within the body.

Other routes such as oral and intravenous are not utilized for Apretude, as the formulation is specifically designed for injection, ensuring optimal absorption and therapeutic effect over an extended period.